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Matrix Metalloproteases (MMPs) and cytokines have been involved in the pathogenesis of multiple sclerosis (MS). However, no
studies have still explored the possible associations between the two families of molecules. The present study aimed to evaluate
the contribution of active MMP-9, active MMP-2, interleukin- (IL-) 17, IL-18, IL-23, and monocyte chemotactic proteins-3 to the
pathogenesis of MS and the possible interconnections between MMPs and cytokines. The proteins were determined in the serum
and cerebrospinal fluid (CSF) of 89 MS patients and 92 other neurological disorders (OND) controls. Serum active MMP-9 was
increased in MS patients and OND controls compared to healthy subjects (𝑝 < 0.001 and 𝑝 < 0.01, resp.), whereas active MMP-
2 and ILs did not change. CSF MMP-9, but not MMP-2 or ILs, was selectively elevated in MS compared to OND (𝑝 < 0.01).
Regarding the MMPs and cytokines intercorrelations, we found a significant association between CSF active MMP-2 and IL-18
(𝑟 = 0.3, 𝑝 < 0.05), while MMP-9 did not show any associations with the cytokines examined. Collectively, our results suggest
that active MMP-9, but not ILs, might be a surrogate marker for MS. In addition, interleukins and MMPs might synergistically
cooperate in MS, indicating them as potential partners in the disease process.
1. Introduction
Multiple sclerosis (MS) is a disease of the central nervous system
(CNS) of supposed autoimmune origin, characterized by
inflammation, demyelination, and neurodegeneration [1].
Although the pathological features of the disease are hetero-
geneous, a common event is thought to be the reactivation
within theCNSof infiltratingmyelin-specificT cells which, in
turn, trigger the recruitment of innate immunity cellsmediat-
ing demyelination and axonal loss [2].The perivascular trans-
migration and accumulation of inflammatory cells within the
CNS are mainly mediated by two events: the production of
leukocyte-attracting chemokines and the blood-brain barrier
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Table 1: Demographic and clinical characteristics of healthy controls and OND and RRMS patients.
Healthy controls (𝑛 = 40) OND (𝑛 = 92) MS (𝑛 = 89)
Age 37.0 ± 7.5; 35.5 (30.3–44.0) 42.4 ± 13.7; 41.5 (33.0–49.0) 39.2 ± 10.9; 37.0 (30.5–48.0)
Sex: female/male 24/16 57/35 53/36
Disease duration (yrs) — — 5.9 ± 7.1; 3 (1–7.7)
EDSS — — 3.8 ± 1.9; 3.5 (2.5–4.4)
Clinically active MS: 𝑛/total (%) — — 32/40 (80%)
Clinically stable MS: 𝑛/total (%) — — 8/40 (20%)
EDSS: expanded disability status scale; MS: multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; OND: other neurological disorders.
(BBB) breakdown [3]. The production of chemokines may
be important for the regulation of the inflammatory cells
influx to sites of tissue damage.Within the chemokine family,
particularly studied members in the course of MS are the
monocyte chemotactic proteins (MCPs), with MCP-1 and
MCP-2 being selectively expressed at high levels in active
lesions, whileMCP-3wasmostly observed in the extracellular
matrix surrounding the vascular elements [4]. In addition
to the establishment of a chemokine gradient, the BBB has
to be disrupted in order for the leukocytes to infiltrate
within the CNS [5]. This event is mediated by the action
of matrix metalloproteinases (MMPs), a family of Zn2+-
dependent and Ca2+-requiring endopeptidases involved in
themodeling of the extracellularmatrix in both physiological
and pathological conditions. Among all MMPs, MMP-9 and
MMP-2 have been extensively studied in MS given their
ability to degrade the components of the basal lamina and to
mediate BBB damage [6–8].
Notably, growing experimental evidence suggests the
involvement of MMP-9 in the pathogenesis of MS, where
its circulating levels in serum and cerebrospinal fluid (CSF)
were found to be upregulated in MS patients compared
with noninflammatory neurological disorders (NIND) and
healthy controls [9–13]. On the contrary, the implication of
MMP-2 in the pathogenesis of MS is more controversial,
since this enzyme had demonstrated both protective [7]
and detrimental actions [14]. Besides MMPs, inflammatory
cytokines, in particular the interleukins belonging to theTh17
axis, IL-23 and IL-17, might also play a role in MS [15].
IL-23, a member of the IL-12 cytokine family, is a het-
erodimeric proteinwith the ability to support the polarization
and expansion of T cells toward aTh17 phenotype [16, 17]. Its
involvement in the pathogenesis of MS has been suggested
by evidence from the animal model of the disease, the
experimental autoimmune encephalomyelitis (EAE). Indeed,
this cytokine has proven to be essential for the development
of EAE [18] and the transfer of Th17 cells, polarized and
expanded by IL-23, was able to induce the disease in animals
[19]. Th17 cells are strictly connected to the pathogenesis of
MS through, but not limited to, the production of several
proinflammatory cytokines including IL-17 (A and F), which
has been found upregulated in chronic lesions of MS patients
[20] and in the serum of Interferon-𝛽 (IFN-𝛽) nonrespond-
ing patients [21]. In addition to the abovementioned factors,
IL-18, another cytokine important in Th1 response in the
course of MS [22], has been found increased in serum and
CSF of MS patients compared to noninflammatory controls,
with the levels of the molecule being higher in those with
MRI gadolinium enhancing lesions [23]. Nonetheless, several
animal and in vitro evidence connected both MMPs to IL-18
[24] and to the IL-17/IL-23 axis [25], demonstrating a general
stimulating effect on the enzymes production, whereas other
reports suggested a regulation of MMP-2 on MCP-3 activity
[26] showing an anti-inflammatory effect [27]. However, to
the best of our knowledge none of the previous studies evalu-
ated the possible interrelationships between the active forms
of MMP-9 and MMP-2 and the most common cytokines
involved in MS pathogenesis. Therefore, in the present study
our aim was to measure the levels of active MMP-9 and
MMP-2, IL-17, IL-18, IL-23, and MCP-3 in the serum and
CSF of MS patients and controls in order to investigate
the contribution of these molecules to MS pathogenesis.
Moreover, we aimed to explore possible interrelationships
between cytokines, MMPs, and clinical variables.
2. Material and Methods
2.1. Patients Selection. For this study, we recruited 89 con-
secutive patients affected by definite relapsing-remitting MS
(RRMS), according toMcDonald criteria [28], who presented
at the Neurology Clinic of the University of Belgrade. Evi-
dence of a relapse at admissionwas considered clinical disease
activity [29]. The data were available for a total of 40 patients
out of 89. Accordingly, 32 patients were clinically active,
whereas 8 patients were clinically stable. Patient disease
severity was measured by Kurtzke’s Expanded Disability
Status Scale (EDSS) [30]. Disease duration was scored and
expressed in years. At the time of sample collection, none
of the patients had fever or other signs of acute infection,
nor had they been receiving any disease-modifying therapies
(DMTs) during the 6 months before the study. A total of 92
controls with other neurological disorders (OND) were also
included in the study (Table 1). OND patients were free of
immunosuppressant drugs, including steroids, at the time of
sample collection. In addition, a total of 40 age- and sex-
matched healthy controls (HC) were used. Informed consent
was given by all patients before inclusion in the study and the
study design was approved by the Ethics Committee of the
School of Medicine, University of Belgrade.
2.2. CSF and SerumSampling. Cerebrospinal fluid and serum
samples were collected under sterile conditions and stored
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in aliquots at −80∘C until assay. “Cell-free” CSF samples
were obtained after centrifugation at room temperature of
specimens taken by lumbar puncture performed for diagnosis
purposes. Serum sampleswere derived fromcentrifugation of
blood specimens withdrawn by puncture of an anterocubital
vein at the same time of CSF extraction. Paired CSF and
serum samples from RRMS and OND patients were stored
and measured under exactly the same conditions. For the
healthy controls, only the serum was available.
2.3. Assay of Interleukins in Serum and CSF. IL-17A, IL-
23, and MCP-3 levels were simultaneously measured in sera
and CSF of patients, twofold diluted with dilution buffer
or undiluted, respectively, by a multiplex sandwich enzyme-
linked immunosorbent assay (ELISA) system based on
chemiluminescence detection (Aushon SearchLight chemi-
luminescent assay kits, Tema Ricerca, Italy) according to the
manufacturer’s recommendations. All samples were analyzed
in duplicate.The interleukin levels are reported as pg/mL.The
lower concentration of each standard curve was 0.78 pg/mL
for IL-17A, 19.5 pg/mL for IL-23, and 0.78 pg/mL for MCP-3.
IL-18 was measured in CSF and serum samples,
twofold diluted, with commercially available ELISA (Boster
Immunoleader cod. EK0864). Samples were assayed in
duplicate. A standard curve was generated in each plate and
the lower standard concentration was 15.6 pg/mL.
2.4. Assay of Active MMP-9 in Serum and CSF. Serum and
CSF levels of circulating active MMP-9 were determined
using a commercially available activity assay system (Human
Active MMP-9 Fluorokine E Kit, R&D systems; Cat. Number
F9M00) following the manufacturer’s instructions. All the
reagents were included in the kit. For the determinations,
a standard curve in the range of 16–0.125 ng/mL was used;
serum and CSF samples were diluted 100 times and 2 times,
respectively, with the calibrator diluent (RD5-24) included in
the kit. According to the manufacturer’s data, the minimum
detectable dose was 0.005 ng/mL and the range of intra-assay
and interassay coefficient of variation (CV) was 3.9–4.8% and
8.0–9.3%, respectively.
2.5. Assay of Active MMP-2 in Serum and CSF. Serum and
CSF levels of circulating active MMP-2 were determined
using a commercially available activity assay system (MMP-2,
Biotrak Activity Assay System, GE Healthcare; Cat. Number
RPN2631) following the manufacturer’s instructions. All the
reagents were included in the kit. For the determinations,
a standard curve in the range of 4–0.125 ng/mL was used;
serum and CSF samples were diluted 25 times and 2 times,
respectively, with the assay buffer included in the kit. Accord-
ing to themanufacturer’s data, the sensitivitywas 0.190 ng/mL
and the range of intra-assay and interassay coefficient of
variation (CV) was 4.4–7.0% and 16.9–18.5%, respectively.
2.6. Statistical Analysis. Normality of distribution was
checked by Shapiro-Wilk test. Since the variables were not
normally distributed, group comparisons were performed
using Kruskal-Wallis followed by Mann-Whitney U tests,
with Bonferroni correction for multiple comparisons. Bivari-
ate correlations were performed by Spearman’s rank test and
frequency distributions were examined using the Chi-square
test. To assess the association between abnormal MMPs and
ILs values measured in serum or CSF and the MS pathology,
a binary logistic regression analysis was performed. A value
of 𝑝 < 0.05 was considered statistically significant.
3. Results
3.1. Active MMP-9 and MMP-2 in Serum and CSF of MS
Patients and Controls. Active MMP-9 and MMP-2 were
detectable in 100% of serum samples and in 100% and in 93%
(85 OND and 84 MS) of CSF samples for MMP-9 and MMP-
2, respectively. As reported in Figure 1(a), the levels of active
MMP-9 were different among the groups. In particular, we
found a higher concentration of active MMP-9 in the serum
of both MS patients and OND controls compared to healthy
subjects (𝑝 < 0.001 and 𝑝 < 0.01, resp.). On the contrary,
active MMP-2 serum levels were similar in MS, OND, and
healthy subjects (Figure 1(b), Kruskal-Wallis 𝐻(2) = 1.009,
𝑝 = 0.604). Then, we compared the amounts of both active
gelatinases measured in the CSF of MS patients and OND
controls. As depicted in Figure 1(c), MS patients showed
almost a doubled concentration of active MMP-9 compared
to OND controls (𝑝 = 0.009), whereas the levels of active
MMP-2 did not differ (Figure 1(d), median (interquartile
range): 4.7 (2.3–11.4) and 5.1 (2.7–10.4) for OND and MS
patients, resp.; 𝑝 = 0.713). When patients were grouped
according to clinical disease activity, there were no statistical
differences between MS patients with and without clinical
evidence of disease activity, for both serum and CSF active
MMP-9 and MMP-2 (data not shown).
3.2. Interleukin Levels in Serum and CSF of MS Patients and
Controls. The levels of IL-17, IL-18, IL-23, and MCP-3 in the
serum of OND and MS patients were detectable in 21% of
samples for IL-17 (16 OND and 22 MS), 86% for IL-18 (79
OND and 77 MS), 71% for IL-23 (65 OND and 64 MS), and
61% for MCP-3 (55 OND and 55 MS). In the CSF, the values
were detectable in 35% of samples for IL-17 (35 OND and
27 MS), 59% for IL-18 (50 OND and 56 MS), 19% for IL-
23 (18 OND and 17 MS), and 53% for MCP-3 (46 OND and
50 MS). As reported in Figures 2(a)–2(d), we did not find
any significant difference in the serum concentration of the
measured cytokines.The same result was observed in theCSF,
where the levels of the cytokines were not different between
the OND controls and the MS patients (Figures 2(e)–2(h)).
When patients were grouped according to clinical disease
activity, we did not find any statistical differences betweenMS
patients with and without clinical evidence of disease activity,
for both serum and CSF IL-17, IL-18, IL-23, andMCP-3 levels
(data not shown).
3.3. Correlations between Interleukin Levels and Active MMP-
9 and MMP-2 in Serum and CSF of MS Patients and
with Clinical Outcomes. We evaluated possible correlations
between the levels ofMMPs and interleukinsmeasured in the
serum of MS patients. As reported in Table 2, we observed
significant positive correlations between MCP-3 and IL-17,
between MCP-3 and IL-23, and between IL-17 and IL-23.
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Figure 1: Median of serum total active MMP-9 and MMP-2, in RRMS patients, OND controls, and healthy donors and CSF active MMP-9
andMMP-2 in RRMS patients and OND controls. Serum levels of total active MMP-9 were statistically different among the groups (Kruskal-
Wallis; H(2) = 15.45, 𝑝 < 0.0001) and CSF active MMP-9 levels were elevated in RRMS patients compared to OND patients. (a) Serum
concentrations of total activeMMP-9were not different amongRRMS (median (IQR): 552 (318–841) ng/mL) andOND(492 (330–737) ng/mL)
patients; whereas they were higher (Mann Whitney; 𝑝 < 0.001 and 𝑝 < 0.01) in RRMS and OND patients when compared to HC (363
(216–482) ng/mL). (b) Serum levels of active MMP-2 were not different between RRMS patients (25.2 (13.1–48.1) ng/mL), OND patients
(26.2 (15.8–52.5) ng/mL), and HC (25.8 (21.8–30.7) ng/mL). (c) CSF amounts of active MMP-9 were more increased in RRMS (0.084 (0.040–
0.165) ng/mL) than in OND (0.046 (0.027–0.113) ng/mL) patients (Mann Whitney; 𝑝 = 0.009). (d) CSF levels of active MMP-2 were not
different between RRMS (5.1 (2.7–10.4) ng/mL) and OND (4.7 (2.3–11.4) ng/mL) controls. IQR: interquartile range; HC: healthy controls;
MMP: matrix metalloproteinase; RRMS: relapsing-remitting MS; OND: other neurologic disorders; CSF: cerebrospinal fluid.
Of note, we did not find any relation between the active
forms of MMPs and the interleukins, although there was a
tendency toward a significant negative correlation between
serum active MMP-9 and IL-18 (𝑝 = 0.076).
Then,we evaluated the correlations between activeMMPs
and interleukins measured in the CSF of patients. The results
are summarized in Table 3. Notably, we found a positive
correlation between IL-18 and activeMMP-2 andMCP-3 and
IL-17 and between IL-18 and IL-23.
There were no significant correlations between disease
severity scored by EDSS, disease duration, and serum and
CSF levels of the measured proteins.
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Figure 2: Continued.
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Figure 2:Median of serumandCSF IL-17, IL-18, IL-23, andMCP-3 concentrations inRRMSpatients andONDcontrols.None of the examined
cytokines/chemokines was different between RRMS patients and OND patients in either the serum or CSF. (a) Serum levels of IL-17 in
RRMS (median (IQR): 33.7 (4.2–335.0) pg/mL) and OND (44.8 (4.1–468.0) pg/mL) patients. (b) Serum levels of IL-18 in RRMS (2259 (1232–
3505) pg/mL) and OND (2266 (1509–3766) pg/mL) patients. (c) Serum levels of IL-23 in RRMS (212.3 (64.9–625.3) pg/mL) and OND (148.9
(54.6–774.9) pg/mL) patients. (d) Serum levels of MCP-3 in RRMS (6.3 (2.6–18.4) pg/mL) and OND (7.5 (3.5–14.7) pg/mL) patients. (e) CSF
levels of IL-17 in RRMS (7.0 (2.0–11.1) pg/mL) and OND (7.1 (2.3–16.1) pg/mL) patients. (f) CSF levels of IL-18 in RRMS (218 (49–551) pg/mL)
and OND (269 (71–644) pg/mL) patients. (g) CSF levels of IL-23 in RRMS (13.4 (5.9–65.9) pg/mL) and OND (18.2 (11.4–57.1) pg/mL) patients.
(h) CSF levels of MCP-3 in RRMS (2.6 (1.5–7.8) pg/mL) and OND (4.3 (1.3–9.1) pg/mL) patients. IQR: interquartile range; CSF: cerebrospinal
fluid; IL: interleukin; MCP: Monocyte Chemoattractant Protein; RRMS: relapsing-remitting MS; OND: other neurological disorders.
Table 2: Correlation matrix of active MMP-9, active MMP-2, and interleukins measured in the serum of MS patients.
Variables (1) (2) (3) (4) (5) (6)
(1) Active MMP-9 —
(2) Active MMP-2 −0.166 (89) —
(3) IL-17 −0.207 (22) 0.290 (22) —
(4) IL-18 −0.204 (77) 0.132 (77) 0.387 (22) —
(5) IL-23 −0.196 (64) −0.017 (64) 0.466 (22)∗ −0.138 (63) —
(6) MCP-3 −0.128 (55) 0.028 (55) 0.922 (21)∗∗ 0.212 (55) 0.468 (48)∗∗ —
Values in brackets represent the degrees of freedom. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01.
3.4. Evaluation of Abnormal MMPs and Interleukin Levels in
Serum and CSF of MS Patients and Controls. Based on the
median values of the activeMMPs and cytokinesmeasured in
the serum or CSF from the whole population, we determined
in all subjects whether the active MMP-9 or cytokines were
increased or active MMP-2 was decreased. These values were
considered abnormal. In addition, the cytokine abnormal
values were merged in one category (Table 4, combined
interleukins), including subjects with at least one abnormal
value of IL-17, IL-18, IL-23, or MCP-3.
As shown in Table 4, we did not find any difference in the
frequency of abnormal levels of either interleukins or MMPs
in serum. The same result was observed when we analyzed
the frequency of patients with abnormal CSF levels of the
considered proteins, with the exception of the active MMP-
9. Indeed, there was a higher proportion of MS patients with
abnormally increased levels of the enzyme compared toOND
controls (Pearson Chi-square (1): 9.335, 𝑝 = 0.002). Then, we
searched for possible association of abnormal levels ofMMPs
and interleukins with MS by employing a binary logistic
regression analysis, considering the diagnosis (MS or OND)
as the outcome variable and entering the abnormal levels
of MMPs or cytokines alone or in combination (combined
interleukins) as predictors. From this analysis, no association
emerged between serum active MMP-9, active MMP-2, or
the cytokines and MS pathology. On the contrary when we
analyzed the proteins measured in the CSF, we found that
only the abnormal values of active MMP-9 were associated
with an increased likelihood of being affected by MS (Odds
Ratio: 2.52, 95% Confidence Interval: 1.39–4.59, 𝑝 = 0.002).
Of note, the inclusion of the other covariates did not improve
the reliability of the model (data not shown).
Finally, we compared the levels of serum or CSF active
MMP-9 and MMP-2 measured in MS patients, grouped
Disease Markers 7
Table 3: Correlation matrix of active MMP-9, active MMP-2, and interleukins measured in the CSF of MS patients.
(1) (2) (3) (4) (5) (6)
(1) Active MMP-9 —
(2) Active MMP-2 0.244 (84) —
(3) IL-17 −0.306 (27) −0.129 (25) —
(4) IL-18 −0.076 (56) 0.300 (53)∗ 0.437 (19) —
(5) IL-23 0.075 (17) −0.344 (16) 0.450 (7) 0.248 (10) —
(6) MCP-3 −0.127 (50) 0.237 (47) 0.485 (20)∗ 0.454 (33)∗∗ 0.575 (13)∗ —
Values in brackets represent the degrees of freedom. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01.
Table 4: Percentage of MS patients and OND controls with
abnormal serum and CSF values.
OND (%) MS (%)
Serum
High active MMP-9 46.7 53.9
Low active MMP-2 53.3 49.4
High IL-17 8.7 12.4
High IL-18 43.5 42.7
High IL-23 32.6 38.2
High MCP-3 30.4 30.3
Combined interleukins 63.0 69.7
CSF
High active MMP-9 40.2 62.9∗∗
Low active MMP-2 51.8 47.6
High IL-17 20.7 13.5
High IL-18 28.3 30.3
High IL-23 9.8 9.0
High MCP-3 28.3 24.7
Combined interleukins 45.7 44.9
The cut-off values used for the determination of the frequency of abnormal
values were as follows.
Serum: active MMP-9, 534 ng/mL; active MMP-2, 25.2 ng/mL; IL-17,
33.6 pg/mL; IL-18, 2262 pg/mL; IL-23, 181 pg/mL; MCP-3, 7.2 pg/mL.
CSF: activeMMP-9, 0.055 ng/mL; activeMMP-2, 5.06 ng/mL; IL-17, 7 pg/mL;
IL-18, 237 pg/mL; IL-23, 15.9 pg/mL; MCP-3, 3 pg/mL.
∗∗
𝑝 < 0.01.
according to the abnormal level of cytokines alone or in
combination.This analysis did not show any difference in the
concentrations of the two MMPs between the patients with
normal or high values of ILs either in serum or in CSF.
4. Discussion
There is evidence connecting both MMPs and Th17/Th1-
related cytokines to the pathogenesis of MS. Indeed, both
families of proteins have been advocated asmarkers of disease
activity [31–33], for therapeutic response [34] and as active
players in theMS disease course [15, 35]. In particular, MMPs
are involved in both BBB disruption and formation of MS
lesions [36], whereas cytokines and chemokines may play
important roles in the recruitment of leukocytes into the CNS
[4] and in the initiation of the autoimmune tissue inflam-
mation [15]. Nevertheless, MMPs and cytokines/chemokines
may also cooperate in the opening of the BBB, a key event that
can further support the leukocyte migration within the CNS
[37]. Notwithstanding the accumulating evidence that might
suggest a possible interplay between MMPs and cytokines,
there is still a lack of clinical studies exploring possible
associations between the mentioned molecules in the serum
and CSF of MS patients.
In light of the above considerations, we set out the
present study with the aim to evaluate the contribution
of MMPs, namely, active MMP-9 and MMP-2, and the
cytokines/chemokines IL-17, IL-18, IL-23, and MCP-3 to the
pathogenesis of MS. More importantly, for the first time
we evaluated the possible intercorrelations involving these
two classes of molecules. In agreement with previous studies
[31, 38], we found that serum active MMP-9 was higher in
patients with MS and OND compared to healthy controls,
whereas the CSF active MMP-9 was selectively elevated in
MS patients. On the contrary, our finding of the lack of
association between serum and CSF levels of active MMP-
2 and MS disagrees with previous observations [32]. In
our view, divergences in patient selection or genetic and
environmental factors [39] might partially explain these
conflicting results.
The lack of difference we found in the serum and CSF
cytokine concentrations also appears in contradiction with
previous reports showing higher serum levels of IL-23 and
IL-18 in MS patients compared to healthy controls [23, 34,
40]. Moreover, other studies showed increased [40] but also
unchanged [34] levels of IL-17 in the serum or PBMC [41] of
MS patients compared to controls.This apparent discrepancy
might be due to a different selection in the control group,
since, at variance of ours, most of the studies compared MS
patients with heathy donors, and to the low detectable rate
of cytokines in both serum and CSF. Of note, to the best of
our knowledge, there are no data in literature about MCP-3
circulating levels.
The observed strong correlations between IL-17, IL-23,
and MCP-3 in the serum and between MCP-3, IL-17, IL-18,
and IL-23 in the CSF of MS patients suggest that, though
not massive, the MS pathology might be characterized by
a general overproduction of cytokines and chemokines.
However, if the overproduction occurs it remains within the
normal values measured in OND controls, since we did not
find any difference in the proportion of abnormal cytokine
levels between the two groups. Collectively, these results
suggest that, at least in our cohort, cytokines might represent
poor surrogate markers of the disease.
8 Disease Markers
On the contrary, active MMP-9, which was selectively
elevated in the CSF of MS patients, could be considered
as appropriate indicator of ongoing inflammation in MS.
Consistently, we found a higher proportion of MS patients
with abnormal CSF levels of active MMP-9 compared to
OND patients, with an increased likelihood of being affected
by MS (Odds Ratio: 2.52). However, the missed correlation
between active MMP-9 and cytokines in either the serum
or CSF (although likely due to the low detection rate of
cytokines) suggests that the activation cascade of the enzyme
might not act in concert with these soluble proinflammatory
factors in the course of MS.
On the other hand, the significant positive correlation
between active MMP-2 and IL-18 suggests that this proin-
flammatory cytokinemight be able tomodulate the activation
cascade of MMP-2. In line with this hypothesis, a recent
in vitro study on neuron-like cells reported an upregulation
of MMP-14, the physiological activator of MMP-2, upon
treatment with increasing amounts of IL-18 [42]. However,
this finding seems in contradiction with the supposed major
role of active MMP-2 in the resolution phase of the disease,
where its levels were lower in patients with MRI evidence of
disease activity [32] indicating a possible anti-inflammatory
action [26]. Of note, we did not find any difference in
both MMPs and cytokine levels between clinically active
and inactive MS patients, suggesting that these molecules
do not seem correlated to clinical exacerbations. However, it
is well known that MRI is superior on clinical examination
in measuring MS disease activity [43], and thus we cannot
exclude that the real contribution of these proteins to the
disease pathogenesis has been underestimated. Indeed, in
previous reports [32, 38] we observed differences in active
MMPs only when patients were categorized in active or
inactive disease based on MRI findings.
This study was not without its limitations. First, the
small sample size may have weakened the consistency of our
data, making it difficult to draw any definitive conclusion
about the possible use of the analyzed molecules as reliable
biomarkers of the disease. Second, the design of the study was
cross-sectional, thereby precluding our ability to establish
any real cause/effect relationship between the cytokines and
MMPs. A longitudinal approach could be more suitable.
Third, the lack of complete data on the clinical activity of the
disease may have mined the ability to detect real differences
between clinically active and stable MS patients. However,
in previous studies we did not find significant differences
when patients were grouped according to clinical evidence of
disease activity [31, 32]. Fourth, the lack ofMRI examinations
in our study could have affected our findings. Finally, the
number of patients and controls with detectable levels of
cytokines was low, limiting the reliability of our results.
Consequently, a replication of the data in larger cohorts of
MS patients and controls is warranted.
In conclusion, although with limitations, our study
confirms that active MMP-9 could be a potential surrogate
marker for monitoring MS disease, whereas cytokines
and chemokines seem not able to discriminate between
MS patients and controls. Nonetheless, our results also
highlighted that MMPs and cytokines might synergistically
cooperate in MS, indicating them as potential partners in
the disease processes. Further studies in a larger number of
patients are needed to verify the effective nature and role
of this cooperation in the modulation of the inflammatory
responses operating in MS.
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